Preventing the Increase in Lysophosphatidic Acids: A New Therapeutic Target in Pulmonary Hypertension?
HPLC-MS/MS
cardiovascular diseases
chronic heart failure
hypertension
lysophosphatidic acids
lysophospholipids
pulmonary hypertension
rodent models
Journal
Metabolites
ISSN: 2218-1989
Titre abrégé: Metabolites
Pays: Switzerland
ID NLM: 101578790
Informations de publication
Date de publication:
17 Nov 2021
17 Nov 2021
Historique:
received:
22
10
2021
accepted:
11
11
2021
entrez:
25
11
2021
pubmed:
26
11
2021
medline:
26
11
2021
Statut:
epublish
Résumé
Cardiovascular diseases (CVD) are the leading cause of premature death and disability in humans that are closely related to lipid metabolism and signaling. This study aimed to assess whether circulating lysophospholipids (LPL), lysophosphatidic acids (LPA) and monoacylglycerols (MAG) may be considered as potential therapeutic targets in CVD. For this objective, plasma levels of 22 compounds (13 LPL, 6 LPA and 3 MAG) were monitored by liquid chromatography coupled with tandem mass spectrometry (HPLC/MS
Identifiants
pubmed: 34822442
pii: metabo11110784
doi: 10.3390/metabo11110784
pmc: PMC8621392
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Agence Nationale de la Recherche
ID : ANR-16-CE17-0012
Références
Adv Drug Deliv Rev. 2020;159:4-33
pubmed: 32730849
J Biol Chem. 2013 Aug 30;288(35):25244-25253
pubmed: 23880760
Lipids Health Dis. 2017 Jul 21;16(1):140
pubmed: 28732508
Am J Physiol Cell Physiol. 2000 Mar;278(3):C612-8
pubmed: 10712250
World J Cardiol. 2017 Feb 26;9(2):76-91
pubmed: 28289523
J Biol Chem. 1995 Jun 2;270(22):12949-52
pubmed: 7768880
Circulation. 2005 Feb 8;111(5):570-5
pubmed: 15699277
J Cell Mol Med. 2014 Jan;18(1):156-69
pubmed: 24251962
Biochem J. 2010 Mar 29;427(2):265-74
pubmed: 20105137
Am J Ther. 2004 Jan-Feb;11(1):54-9
pubmed: 14704596
Molecules. 2020 Sep 20;25(18):
pubmed: 32962299
Cell Physiol Biochem. 2017;43(1):282-292
pubmed: 28854428
Pulm Circ. 2014 Sep;4(3):471-81
pubmed: 25621161
Biochim Biophys Acta. 2010 Mar;1798(3):354-9
pubmed: 19958748
Mol Cell Biochem. 1994 Dec 21;141(2):135-43
pubmed: 7891671
Biochim Biophys Acta. 2011 Dec;1810(12):1170-7
pubmed: 21914461
Am J Respir Cell Mol Biol. 2013 Dec;49(6):912-22
pubmed: 23808384
Pharmacol Ther. 2019 Dec;204:107404
pubmed: 31472182
Redox Biol. 2019 May;23:101119
pubmed: 30833142
Stem Cells Int. 2011;2011:916180
pubmed: 21876704
J Am Geriatr Soc. 2019 Oct;67(10):2038-2044
pubmed: 31287932
J Biol Chem. 2009 Sep 4;284(36):24123-32
pubmed: 19586906
Clin Lipidol. 2011 Aug;6(4):413-426
pubmed: 22162980
Curr Opin Lipidol. 2015 Oct;26(5):432-7
pubmed: 26270808
FEBS Lett. 2000 Jul 28;478(1-2):159-65
pubmed: 10922489
World J Gastroenterol. 2018 Sep 28;24(36):4132-4151
pubmed: 30271079
Yale J Biol Med. 2007 Jun;80(2):51-60
pubmed: 18160990
Pulm Pharmacol Ther. 2018 Jun;50:111-122
pubmed: 29673911
Am J Physiol Heart Circ Physiol. 2011 Dec;301(6):H2181-90
pubmed: 21949114
Am J Physiol Lung Cell Mol Physiol. 2011 Oct;301(4):L547-56
pubmed: 21821728
Curr Opin Cardiol. 2016 Jul;31(4):440-50
pubmed: 27205885
Healthcare (Basel). 2017 Jun 21;5(2):
pubmed: 28635680
Cardiovasc Res. 2020 Mar 1;116(3):686-697
pubmed: 31173066
Biochim Biophys Acta. 2008 Sep;1781(9):563-70
pubmed: 18586114
Arterioscler Thromb Vasc Biol. 2012 Jan;32(1):24-32
pubmed: 22015657
J Chromatogr A. 2014 Jun 20;1347:104-10
pubmed: 24813932
J Mol Cell Cardiol. 2012 Mar;52(3):660-6
pubmed: 22155238
Methods Mol Biol. 2010;610:403-17
pubmed: 20013192
Curr Protoc Mol Biol. 2012 Apr;Chapter 30:Unit 30.2.1-24
pubmed: 22470063
Lipids Health Dis. 2011 Oct 04;10:174
pubmed: 21970553
J Clin Invest. 2001 Oct;108(8):1141-50
pubmed: 11602621
Hypertension. 2004 Apr;43(4):693-8
pubmed: 14967829
Nat Med. 2008 Jan;14(1):45-54
pubmed: 18066075
J Am Coll Cardiol. 2009 Jun 30;54(1 Suppl):S20-S31
pubmed: 19555855
EPMA J. 2011 Mar;2(1):27-38
pubmed: 21654904
J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021
pubmed: 33309175
Sci Rep. 2016 Nov 24;6:37585
pubmed: 27883026
Sci Rep. 2019 Feb 25;9(1):2662
pubmed: 30804442